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A B S T R A C T
Closure of ocular wounds after an accident or surgery is typically performed by suturing, which is associated
with numerous potential complications, including suture breakage, inﬂammation, secondary neovascularization,
erosion to the surface and secondary infection, and astigmatism; for example, more than half of post-corneal
transplant infections are due to suture related complications. Tissue adhesives provide promising substitutes for
sutures in ophthalmic surgery. Ocular adhesives are not only intended to address the shortcomings of sutures,
but also designed to be easy to use, and can potentially minimize post-operative complications. Herein, recent
progress in the design, synthesis, and application of ocular adhesives, along with their advantages, limitations,
and potential are discussed. This review covers two main classes of ocular adhesives: (1) synthetic adhesives
based on cyanoacrylates, polyethylene glycol (PEG), and other synthetic polymers, and (2) adhesives based on
naturally derived polymers, such as proteins and polysaccharides. In addition, diﬀerent technologies to cover
and protect ocular wounds such as contact bandage lenses, contact lenses coupled with novel technologies, and
decellularized corneas are discussed. Continued advances in this area can help improve both patient satisfaction
and clinical outcomes.
1. Introduction
Microsurgical suturing of ocular, in particular corneal, wounds is
often associated with numerous drawbacks including post-operative
astigmatism and requires a relatively high level of skill from the sur-
geon. Sutures can also provoke inﬂammation, lead to vascularization,
and increase the risk of microbial infection, among other problems
[1–5].
Ocular adhesives are promising alternatives to sutures. Sealants or
adhesives have been used in ophthalmology for nearly ﬁve decades
[6,7]. These materials are typically polymers that are applied as ﬂuids
at the ocular wound site and are chemically or physically crosslinked to
bind and hold tissues. Ocular adhesives not only prevent the patient and
the surgeon from experiencing the drawbacks of sutures, but also can
potentially oﬀer important functionalities that are otherwise not easily
attained. Some of these key added functionalities could be of great
beneﬁt to the patient, e.g. the feasibility to match the adhesive bio-
mechanical properties to those of the native tissue, so the wound
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healing progresses without limiting tissue movement or aﬀecting its
function. Moreover, the adhesive material can be functionalized with
pharmacological or biological compounds that prevent infection and
inﬂammation and/or promote tissue regeneration.
The human eye architecture is highly complex; it possesses several
layers of tissue precisely organized to allow the passage of light
(Fig. 1A). An ideal ocular adhesive should meet a number of char-
acteristics depending on their speciﬁc application and the anatomical
parts involved in the medical intervention (Fig. 1B). Generally, it
should be biocompatible, non-toxic, comfortable for the patient, easily
and rapidly applied, adhesive to the ocular tissue, quickly seal the in-
jured area, mimic the mechanical properties of the tissue, permeable to
nutrients and gases, and oﬀer a microbial barrier. Speciﬁc applications,
such as corneal sealing, demand other characteristics such as trans-
parency and a refractive index similar to the cornea. Additional desir-
able characteristics include cost-eﬀectiveness, long storage stability,
and the possibility of incorporating drugs or biological compounds
[2,8,9].
Historically, commercial cyanoacrylate-based multi-purpose glues
were the ﬁrst adhesives used in ophthalmic practice, albeit used ‘oﬀ-
label’ without Food and Drug Administration (FDA) or other regulatory
authority approval [10]. These adhesives oﬀer fast and facile wound
closure, but they are cytotoxic to eye, possess a rough texture, require
use of a ‘bandage’ contact lens and are very opaque precluding good
vision when applied to the central cornea or examination of subjacent
tissues by the examiner, thus not permitting evaluation of healing.
Later, collagen-based adhesives appeared as a more biocompatible al-
ternative to cyanoacrylate; however, they have low mechanical stability
and adhesion strength. New strategies in biomaterials engineering have
led to the formation of more advanced ocular adhesives [10]. These
adhesives can be engineered from synthetic or natural polymers to
match the physical properties of the native ocular tissue, and to tune
their adhesion strengths. This design versatility allows for the
development of eﬀective ocular adhesives and sealants capable of
closing wounds without impeding tissue movement and functions.
Herein, we review a spectrum of ocular adhesives ranging from
synthetic materials (cyanoacrylates, PEG-based and dendrimers) to
naturally derived polymers (proteins and polysaccharides).
Fundamentals related to biomaterial design such as chemical nature,
preparation methods, and physicochemical properties are discussed. In
addition, the advantages and limitations of currently available ocular
adhesives are summarized. We also discuss the concept of ocular ad-
hesives as drug-delivery vehicles, and brieﬂy review contact bandage
lenses as an alternative to sealants in eye-wound-care. Finally, advances
towards the development of functional decellularized corneas using
biomaterials are described.
2. Synthetic polymer-based tissue adhesives
Synthetic adhesives are materials often used in a wide spectrum of
healthcare applications, including ophthalmology. These materials
oﬀer high tunability of a number of characteristics for speciﬁc oph-
thalmic applications such as chemical compositions, mechanical prop-
erties, tissue adhesiveness, and degradation kinetics. Moreover, syn-
thetic adhesives present added beneﬁts with regard to ease of
manufacturing, high purity, and low cost. The most widely explored
synthetic adhesives used in ophthalmology are based on cyanoacrylates
and linear PEG derivatives.
2.1. Cyanoacrylate-based ocular adhesives
Cyanoacrylate-based adhesives, also known as “superglues”, are
synthetic, multi-purpose tissue adhesives that have been used for a
variety of general household usages as well as biomedical applications
[11]. Bloomﬁeld et al. were the ﬁrst to report the ophthalmic in vivo use
of methyl 2-cyanoacrylate in a rabbit model [12]. They applied the
Fig. 1. Eye anatomy, cornea structure, and desirable characteristics of an ocular adhesive. (A) Anatomy of (i) eye and (ii) cornea. (B) Biological, chemical,
physical, and practical characteristics that an ideal ocular adhesive should exhibit.
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adhesive topically to the conjunctiva and the cornea, and sub-con-
junctively to the sclera, which resulted in a tight wound closure in the
ﬁrst few postoperative days. Since this ﬁrst report, the use of cyanoa-
crylates has become popular in ophthalmology. In ocular surgeries,
cyanoacrylate-based adhesives are frequently used by ophthalmologists
to seal eye wounds. Although they are not approved by FDA for clinical
ophthalmic use [13], these adhesives are used as an oﬀ-label for various
applications such as cataract wound repair [14–21], leaking blebs
[22–27], retinal detachment [28–31], scleral reinforcement [32], at-
tachment of muscles to ocular prosthetics [33,34], punctual occlusion
[35,36], blepharoplasty [37–39], temporary tarsorrhaphy [40–42],
closure of corneal perforations [42], treatment of amblyopia [43], re-
moval of deep corneal foreign bodies [44], stromal thinning repair
[42], corneal descemetoceles [45], and exposure keratopathy [42,46].
Although cyanoacrylate-based adhesives oﬀer a quick, eﬀective, and
easy treatment of ocular wounds, they have several drawbacks in-
cluding discomfort to the patient, cytotoxicity, and many other lim-
itations that will be discussed in this section.
Cyanoacrylates are monomeric alkyl esters of α-cyanoacrylic acid,
which can be readily prepared via a condensation reaction between
alkyl cyanoacetate and formaldehyde aided by a catalyst [47]. In gen-
eral, cyanoacrylates have a high propensity to participate in poly-
merization reactions, which can proceed via an anionic or zwitterionic
mechanism (Fig. 2A). These reactions are initiated through a nucleo-
philic attack of alcohols, water, or amino acids present in the living
tissues, and can later propagate to form alkyl methacrylate polymers
[48]. The initiation reaction by amino acid residues of proteins is key
for the strong binding of cyanoacrylate adhesives to the tissues [49].
Such strong binding, along with appropriate biomechanical properties
and rapid polymerization (i.e. within 10–60 s), has made cyanoacrylates
attractive for diﬀerent medical applications.
However, the application of cyanoacrylate has been associated with
irregular rough surfaces, heat generation, rapid polymerization, and
cytotoxicity, limiting its usage for ophthalmic applications. Fast poly-
merization rate of cyanoacrylate is a characteristic that works both in
favor and against this adhesive. While fast polymerization makes the
process of sealing time-eﬃcient and minimizes discomfort to the pa-
tient, it also complicates its application for the physician. For instance,
in cornea perforation sealing, it is important to control the moisture of
the tissue surface, and to rapidly apply a proper dose of cyanoacrylate
so that a thin and even layer of the cyanoacrylate polymerizes in place
to hold the tissue eﬀectively [50]. Given these challenges, the selection
of the proper technique for the application of cyanoacrylate-based ad-
hesives in a particular intervention becomes critical for a successful
clinical outcome. Rana et al. summarized diﬀerent techniques to apply
cyanoacrylate glues in corneal perforations [50]. The traditional
Fig. 2. Structure, properties and clinical applications of cyanoacrylate based adhesives. (A) Preparation and anionic polymerization reaction (crosslinking) of
cyanoacrylate monomers. Adapted from Scognamiglio et al. [61] with permission from Wiley, copyright 2016. (B) Cyanoacrylate based glue applications, (i)
traditional technique: direct application of a drop of cyanoacrylate glue on a pre-dried ocular tissue, and (ii) patient eye treated with this technique; (iii) infant
cannula technique: a small disc of a non-adhesive material is cut with a punch biopsy, an infant cannula (without needle) is used to pick up and hold the disc, a drop
of glue is applied on the disc, and ﬁnally the glue is placed gently on the pre-dried ocular tissue, (iv) patient eye treated with this technique, (v) corneal tissue
repaired with this technique. Adapted from Rana et al. [50] with permission from Elsevier, copyright 2013. (C) A polyglactin mesh glued with cyanoacrylate on a
cadaver eye for strabismus surgery application, and eﬀect of the polymerization time and surface area on the bonding strength of the mesh to the eye tissue. Adapted
from Bona et al. [60] with permission from Elsevier, copyright 2014.
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technique consists of drying the ocular surface and gently adding a
small drop of the cyanoacrylate glue on the aﬀected tissue with a 20-
gauge needle or other pointed instrument (Fig. 2Bi). This method was
successfully used for small perforations. For larger ocular wounds, they
also used a modiﬁed method, which consisted of cutting a small non-
adhesive bandage or surgical drape with a skin biopsy punch, holding
this bandage with an infant cannula (without a needle) or with any
small rod or applicator that can maintain adequate adhesion to the
drape, adding a drop of glue on the bandage, and placing the bandage
with the glue on the aﬀected area (Fig. 2Biii). Their results showed that
the proper choice of the application techniques alone could result in
improved surgery outcomes, even when using the same glue (Fig. 2B);
however, controlled application of cyanoacrylate glue to any surface,
including the surface of the eye, remains a challenge.
Cytotoxicity is another notable drawback of cyanoacrylates ad-
hesives [51]. It is caused by the rapid degradation of the adhesives into
cyanoacetate and formaldehyde, which can accumulate in tissues and
induce acute and chronic inﬂammation [13,52]. Various derivatives of
cyanoacrylate esters such as n-butyl, n-heptyl, methoxypropyl, and
octyl cyanoacrylates, have been developed to diminish cytotoxicity and
lower the polymerization rate [6,53]. In general, cyanoacrylates with
shorter alkyl chains show higher reactivity, faster degradation rate, and
more serious toxic eﬀects on tissues than their counterparts with longer
alkyl chains [54]. Moreover, it has been reported that the tissue binding
strengths of cyanoacrylate adhesives are inversely correlated with the
lengths of the side chains (e.g., butyl cyanoacrylate had stronger
binding than octyl cyanoacrylate) [55]. However, this is not a uni-
versally valid statement. Ricci et al. reported that octyl 2-cyanoacrylate
achieved superior tensile strengths when bonding between the sclera
and the muscle, as well as better adhesion at the edges of the wound,
than cyanoacrylates with shorter alkyl chains such as methyl 2-cya-
noacrylates. Cyanoacrylate adhesives have also shown some level of
bacteriostatic and bactericidal eﬀects [53]. Butyl 2-cyanoacrylate and
ethyl 2-cyanoacrylate exhibited bacteriostatic eﬀects on Gram-negative
and Gram-positive microorganisms in vitro and in vivo, especially when
the adhesive was polymerized in situ [56–58].
Cyanoacrylates can also be used in combination with other mate-
rials to improve their performance in particular interventions. For ex-
ample, Lee et al. prepared a hybrid adhesive composed of pre-poly-
merized allyl 2-cyanoacrylate (PACA) mixed with poly L-lactic acid
(PLLA) [59] to enhance the biocompatibility and mechanical properties
of cyanoacrylates. Bona et al. reported using composite materials based
on cyanoacrylates to enhance support and bonding strength in the
context of strabismus surgery [60]. In this kind of surgery, there is need
for a method to bond a suﬃcient area of sclera and extraocular muscles
to avoid tissue slippage. For this purpose, the authors glued a poly-
glactin mesh with a butyl cyanoacrylate adhesive on the sclera of ca-
daveric eyes. Then, the mesh served as a scaﬀold to be attached to the
muscle. They investigated the eﬀects of polymerization time and mesh
size (covered area) on bonding strength (the force needed to remove the
mesh from the sclera). They demonstrated an improved adhesion with
longer polymerization times and larger mesh areas (Fig. 2C). This study
provided a clinically relevant method to complement traditional pro-
tocols for bonding muscle to sclera in strabismus surgeries [60]. These
studies suggest that the combination of cyanoacrylates with other ma-
terials can be used to engineer ophthalmic adhesives with enhanced
performance.
In summary, despite their advantages (i.e. quick, easy, and eﬀective
treatment of ocular injuries), and their frequent oﬀ-label use in oph-
thalmic applications, the use of cyanoacrylates has been hampered by
many shortcomings including infection [62], corneal endothelial poly-
merization [63], granulomatous keratitis [64], dacryocystitis [65],
symblepharon formation [66], and unintentional entry into the anterior
chamber [67]. In addition, the non-biodegradable nature of cyanoa-
crylates can lead to inﬂammatory responses, corneal neovasculariza-
tion, foreign-body reactions, and tissue necrosis. Moreover, the
application of cyanoacrylates in ophthalmic surgeries is limited due to
the rigid, inﬂexible nature of the solidiﬁed adhesives, which is im-
permeable to ﬂuid and metabolites, thus remaining as a foreign body. In
addition, the non-bioabsorbable nature, lack of transparency, and
rough surface limit healing of the underlying tissue, occlude vision, and
cause discomfort when blinking [4,5,53,68]. Continued progress to-
ward the modiﬁcation of cyanoacrylates should alleviate some of the
side-eﬀects associated with their applications in ophthalmology.
Moreover, engineering hybrid materials composed of cyanoacrylates
and biocompatible polymers can be envisioned to aﬀord better bioad-
hesives with enhanced biocompatibility than that of pure cyanoacry-
late-based adhesives.
2.2. PEG–based adhesives
PEG and its derivatives are frequently used for a wide range of
biomedical purposes due to their remarkable advantages such as good
solubility in both non-polar and polar solvents, antifouling properties,
nontoxicity, and low immunogenicity [69]. In addition, the PEG
backbone is amenable to a wide variety of chemical modiﬁcations,
which makes it very versatile. For instance, PEG-based hydrogels have
been functionalized with biochemical cues to tune their bioactivity,
biodegradability, and mechanical properties, among others [70–72].
This versatility makes PEG an appealing material for ocular adhesives.
In this section, we review PEG-based ocular glues, including those al-
ready in clinical use, and others currently under research and devel-
opment.
ReSure® is an FDA-approved, PEG-based ocular adhesive. This pro-
duct is speciﬁcally used to seal clear corneal incisions (CCI) commonly
used in cataract surgery, and for the preclusion of ﬂuid egress after
cataract surgery [73]. ReSure® adhesive is based on two components: an
N-hydroxysuccinimide (NHS)-terminated 4-arm PEG prepolymer and a
tri-lysine amine crosslinker, which can yield stable hydrogels in less
than 30 s after mixing. Clinical studies have shown several advantages
of ReSure® over sutures such as improved comfort to the patient, faster
healing, and better lubrication properties. In addition, ReSure® can
sustain higher intraocular pressures (IOP; from 11 to 29mmHg) [74],
and it is more eﬃcient than sutures in averting ﬂuid egress in cataract
surgery and in single-plane incisions (i.e. 4.1% and 34.1% ﬂuid egress
for PEG-based adhesive and suture groups, respectively) [73]. ReSure®
has been also used in conjunction with ﬂap lifting and scraping to
prevent the recurrence of epithelial ingrowth [75] in laser-assisted in
situ keratomileusis (LASIK) surgery. In addition, due to its synthetic
origin, ReSure® does not facilitate virus transmission, whereas other
natural-based polymers might. However, ReSure® has some drawbacks
and limitations. For example, the requirement for mixing of two com-
ponents, and the need of rapid application after mixing (14–17 s) can be
challenging in some circumstances. Also, ReSure® can only be used to
seal incisions that are not actively leaking, and once applied it is stable
for periods of no longer than 3 days [76]; additionally, it cannot ﬁll in
stromal defects (unlike cyanoacrylate) and can fall oﬀ easily when not
covered by tissue [10,76].
Alternative strategies have been reported to produce PEG-based
hydrogel adhesives for ophthalmological use. These hydrogels are often
produced by functionalizing the chain ends of linear PEG with acrylate,
methacrylate, or other groups that are subject to free radical poly-
merization (e.g. poly (ethylene glycol) diacrylate (PEGDA)). Aided by a
photoinitiator such as Eosin Y or Irgacure 2959, initiation of the free
radical polymerization of the reactive groups on modiﬁed PEG deri-
vatives can occur upon exposure to visible light [70] or ultra violet
(UV) light [77], rendering 3D hydrogel networks (Fig. 3Ai) [78].
The mechanical and biological performance of PEG-based hydrogels
can be tuned by altering their physicochemical properties, such as
polymer concentration, molecular weight of the PEG backbone, and
crosslinking methods, among others. For instance, prepolymer con-
centration has been reported to have an important eﬀect on mechanical
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properties, and therefore, the viability of encapsulated cells in the re-
sulting hydrogel. Typically, increasing prepolymer concentration re-
sulted in a higher compressive modulus, but may limit cell viability and
proliferation in the 3D matrix [79]. The molecular weight of the PEG
prepolymer can also aﬀect the mechanical properties and swellability of
PEG-based hydrogels. The wide-range tunability of the physical prop-
erties of PEG hydrogels enables the rational design and optimization of
PEG-based adhesives in ophthalmology. For example, Yañez-Soto et al.
[72] reported the development of PEGDA hydrogels for human corneal
epithelial cell (HCEC) 2D cultures (Fig. 3Aii). The authors produced
hydrogels with particular topographic features by using a cast molding
technique, and then immersed them into water until swelling equili-
brium was reached. They found that the resolution of the topography
was related to the molecular weight and concentration of the PEGDA
used to form the hydrogel. In order to obtain high-resolution features,
the ratio between the hydrogel volume before and after equilibrium
swelling had to be low, which was achieved by lowering the PEGDA
molecular weight, and polymer concentrations [72] (Fig. 3Aii).
Interestingly, the molecular weight also had an eﬀect on non-speciﬁc
binding of HCECs. Flat hydrogels fabricated with low molecular weight
PEGDA (700 g/mol) rendered a higher degree of nonspeciﬁc cell
binding than that of higher molecular weight PEGDA (3400 g/mol;
Fig. 3Aiii).
PEG-based hydrogels are known to inhibit non-speciﬁc binding of
cells. However, enhanced cellular interaction with PEG-based hydrogels
can be achieved via chemical modiﬁcation to introduce peptide cell
binding motifs. For example, PEGDA hydrogels can be modiﬁed by a
Michael addition of cysteine-bearing arginylglycylaspartic acid (RGD)
peptides (Fig. 3Bi) to enable speciﬁc RGD-integrin attachment of HCECs
to the PEGDA hydrogel surface (Fig. 3Bii and 3Biii). This ﬂexibility of
chemical modiﬁcation aﬀords a diverse range of functions of PEG-based
adhesives [80].
Hoshi et al. used a porcine ex vivo model in which the retina was
detached after the vitreous gel was removed from the eyecups, and a
PEG-based adhesive (FocalSeal® from Genzyme Corporation) was ap-
plied to cover the tear. Upon exposure to xenon light (450–500 nm) for
Fig. 3. Molecular structure and properties of PEG-based adhesives. (A) PEGDA synthesis (i) PEG functionalized with diacrylated groups formed a 3D hydrogel
network in the presence of a photoinitiator upon exposure to light. Physical and biochemical properties of resulting hydrogels were customized by modifying
hydrogel formulations. (ii) Eﬀect of PEGDA molecular weight on water swelling behavior and on pattern resolution on molded PEGDA hydrogels. (iii) Eﬀect of
PEGDA molecular weight on non-speciﬁc cell attachment. Adapted from Yanez-Soto et al. [72] with permission from Wiley, copyright 2013. (B) (i) Chemical
modiﬁcations to functionalize PEGDA hydrogels with RGD peptide motifs, micro-molded PEGDA hydrogels (ii) with and (iii) without RGD functionalization to tune
cell attachment and to direct the alignment of human coronal epithelial cells. Scale bar: 100 μm. Adapted from Yanez-Soto et al. [72] with permission from Wiley,
copyright 2013. (C) (i) Scheme of the sealing of scleral incisions using PEG adhesive, (ii) Photographic images of sealing of a scleral incision in a rabbit vitrectomy
model with PEG adhesive, (iii) Photographs of sectioned samples of a sclerotomy site closed with the PEG-based adhesive (the conjunctival incision is indicated by
the arrow). Excessive inﬂammation is not evident. (Scale bar: 500 μm). Adapted from Hoshi et al. [81] with permission from Association for Research in Vision and
Ophthalmology, copyright 2016.
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Fig. 4. Structure, properties, and applications of dendritic adhesives. (A) Schematic illustration of diﬀerent generations of dendritic adhesives from G0 to G4,
which were prepared via divergent synthesis. The central core, inner branches, and peripheral groups were three main structural regions of these macromolecules.
Adapted from Grinstaﬀ et al. [99] with permission from Wiley, copyright 2002. (B) A method to apply and crosslink a ([G1]-PGLSAMA)2-PEG dendritic adhesive. An
incision of 4.1 mm was made on enucleated eye cornea, 15–20 μL of adhesive was placed on the surface of the pre-dried wound, the adhesive was photocrosslinked
using argon laser (diﬀuse beam; 200mW; 1 s), the sealed wound withstood an IOP of 109.6 ± 82.7 mmHg before leakage. Adapted from Velazquez et al. [98] with
permission from American Medical Association, copyright 2004. (C) Images of histology transversal cuts of chicken cornea wounds treated with a ([G1]-PGLSAMA)2-
PEG dendritic adhesive and suture after 28 days. Adapted from Grinstaﬀ et al. [2] with permission from Elsevier, copyright 2007. (D) Dendrimers used as crosslinking
agents of collagen hydrogels. (i) Mechanical properties and (ii) cell growth of collagen hydrogel crosslinked with generation 2 polypropyleneimine octaamine
dendrimer compared to collagen hydrogels crosslinked with 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide hydrochloride and glutaraldehyde. Adapted from
Duan and Sheardown et al. [97] with permission from Elsevier, copyright 2006.
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40–60 s, the prepolymer solution formed a solid, crosslinked hydrogel.
The adhesive remained attached for 24 h despite a forceful squirt of
balanced salt solution, showed little inﬂammatory reaction in the eyes
during 28 days of follow up, and the electroretinography also did not
show any abnormality or inﬂammation [81]. In addition, the authors
also conducted an in vivo study to investigate the application of this
photo-curable PEG-based sealant for the closure of sutureless sclero-
tomies (surgical incision of the sclera) in microincisional vitrectomy
surgery (MIVS) using a Dutch pigmented rabbit eye model (Fig. 3Ci).
They showed that 23-gauge vitrectomy incisions in rabbit eyes could be
successfully closed by this photocured, PEG-based adhesive (Fig. 3Cii)
and that the sealant did not cause immoderate inﬂammation as ob-
served by histological analysis (Fig. 3Ciii).
PEG terminals can be also functionalized with nucleophilic groups,
which will subsequently react with electrophilic groups of a second
component. However, the selection of the proper nucleophile-electro-
phile chemistry that can take place quickly at the body temperature
under physiological conditions, without producing toxic by-products,
has proven to be challenging. In addition, such reactions require a high
degree of chemoselectivity between the designed nucleophile-electro-
phile pairs, due to the presence of a wide range of other functional
groups such as amines, thiols, hydroxyls, and carboxylates in native
tissue environments, which may interfere with the crosslinking reac-
tion. For example, PEG functionalized with amines and thiols can react
with complementary N-hydroxysuccinimide esters to form amide or
thiol ester crosslinked hydrogels, respectively. Depending on the mo-
lecular weights of PEGs and the prepolymer concentrations, hydrogels
could form in 5 s to 5min [82]. Linear PEGs functionalized with suc-
cinimidyl succinate (SS) or succinimidyl propionate (SPA) groups could
form crosslinked networks with a complementary tetra-functional
amine-terminated PEG, which could tolerate higher load before failure
than ﬁbrin-based adhesives or photocrosslinkable acrylic adhesives.
Even though the hydrogels made from PEG-SPA have superior me-
chanical properties and stability (up to several months), histological
evaluation revealed that these adhesives can cause severe damage when
applied to rabbit's eyes [83]. Moreover, hydrogels fabricated from PEG
functionalized with succinimidyl glutarate (SG) and thiol groups
showed superior mechanical properties compared with the PEG-SPA
and PEG-SS based adhesives [83]. Kalayci et al. reported that the NHS-
terminated 4-arm succinimidyl-glycolate PEG and complementary
amine-functionalized 4-arm PEG could form crosslinked hydrogels in
seconds, which were stable for up to six weeks. Application of this
hydrogel to central corneal incisions that were 1–5mm in size in suc-
cessfully sealed the incision in an ex vivo rabbit model. Also, the ad-
hesive-treated eyes could tolerate higher leaking pressure in all wound
models compared with a suture-treated eye [84], thus suggesting the
potential of these adhesives for successful eye wound closure.
The use of PEG-based materials has also been extended to develop
artiﬁcial corneas [85]. For example, the interpenetrating network of
PEG functionalized with poly (acrylic acid) exhibited desirable me-
chanical properties, transmissibility and diﬀusion coeﬃcients (i.e.
Young's modulus of 2MPa for 20% (w/w) concentration, 96% light
transmissibility and ideal diﬀusion coeﬃcients for oxygen and nu-
trients). In vivo application of this hybrid adhesive showed long-term
stability and suﬃcient biocompatibility in a rabbit model [85].
2.3. Dendrimer-based adhesives
Dendrimers are polymeric repetitive hyper-branched macro-
molecules that have gained attention in the scientiﬁc community be-
cause of their particular physical and chemical properties such as
multifunctionality, monodispersed molecular weights, and high surface
area to volume ratio [86–89]. Such properties, along with their highly
tunable chemical structures, make them suitable for various biomedical
applications [90] including the development of sealants and bioadhe-
sives [91]. A dendrimer can be synthetized by the chemical
condensation of successive layers of monomers from a central moiety
(divergent synthesis), or by the synthesis of multiple branches to later
fuse them to a central core (convergent synthesis). In any case, the
result is a highly symmetric and hyper-branched macromolecule that is
structurally composed of three main zones: the central core, the internal
branching layers, and the peripheral moieties [90,92,93].
Dendrimers can be synthesized from natural metabolic compounds
including amino acids such as lysine, valine, and leucine [93], sugars
[94], α-hydroxy acids, fatty acids [92], and metabolic intermediates,
such as citric acid, fumaric acid, pyruvic acid, and succinic acid
[95,96]. Along with these small-molecule monomers, modiﬁed mac-
romers based on PEG, polycaprolactone (PCL), and polytrimethylene
carbonate (TMC), among others, oﬀer additional ﬂexibility in terms of
monomer selection and the ability to match dendrimer structures to
speciﬁc functional needs [2].
In a dendrimer, each layer is called a generation (G). As the number
of generations (Gn) increases, the dendrimer becomes more branched
(e.g. G0 vs. G4) (Fig. 4A) and much larger. Dendrimers can be cross-
linked to form 3D hydrogel networks. Crosslinking methods for den-
drimers are very similar to those described for PEG-based adhesives: (i)
chemical modiﬁcation with acrylate groups to further photopolymerize
the polymer in a presence of a photoinitiator, and (ii) modiﬁcation with
nucleophilic groups that will react with electrophilic groups of a second
polymer [2]. Dendritic molecules can be used as the bulk polymers to
provide adhesiveness to hold the tissue, create a protective barrier to
cover the ocular wound, or as the crosslinker for another polymer that
constitute the main network (e.g. PEG and collagen) [97].
Grinstaﬀ et al. [2] synthesized a series of ﬁrst-to fourth-generation
(G1-G4) photocrosslinkable hybrid dendrimers to seal corneal lacera-
tions. These dendrimers, termed ([Gn]-PGLSA)2-PEG, were synthesized
from PEG, glycerol, and succinic acid units [91]. A method to seal a
linear incision in an ocular globe using these photocrosslinkable den-
dritic adhesives is shown in Fig. 4B. First the incision was made in the
ocular tissue, a precise amount of the dendrimer-based sealant was
applied on the pre-dried wound, and ﬁnally photocrosslinked using a
laser beam (argon ion; 200mW; 1 s) [98]. Recent studies reported
diﬀerent generations of dendritic copolymers of PEG, glycerol, and
succinic acid [([Gn]-PGLSA-MA)2-PEG, n= 0–4] as candidates to repair
corneal lacerations [78,99]. Both the chemical nature and the overall
architecture of the dendrimer (i.e. degree of branching, number of
generations) can determine the functionality of the ocular adhesive. For
instance, Grinstaﬀ et al. found that the [([G0]-PGLSA-MA)2-PEG] co-
polymer was not able to eﬀectively crosslink to aﬀord leak-tight sealing,
and larger generations could be easily peeled oﬀ without providing a
suﬃcient sealing [99]. Overall, ([G1]-PGLSA-MA)2-PEG exhibited the
best performance in ocular globes with a linear incision [99]. The re-
corded leaking pressure from this adhesive (109.6 ± 82.7mmHg) ex-
ceeded that of a traditional suture treatment (75 ± 27.8 mmHg).
Moreover, this dendrimer-based adhesive showed adequate eﬃciency
to repair corneal perforations of 4.1mm, to seal the ﬂap originated in a
LASIK operation, and to secure a transplant of cornea ex vivo [98–100].
An in vivo chicken model was used to test ([G1]-PGLSA-MA)2-PEG
for corneal wound healing [2]. A volume of 20 μL of the dendritic
adhesive was applied on 4.1mm full-thickness linear corneal wounds
and subsequently crosslinked upon exposure to a laser, resulting in
successful sealing of 97% of the laceration. While the adhesive fully
degraded by day 14, the lacerations sealed with the dendritic for-
mulation showed a more uniform histology compared with the corneal
wounds treated with sutures. The histological cross-sections of the
tissue repaired using [G1]-PGLSA-MA)2-PEG dendritic adhesive after 28
days showed that the dendritic adhesives led to a smoother stromal
layer, with no discontinuities of Bowman's layer and no detachment of
the stromal and epithelial layer, compared to tissue repaired with su-
tures (Fig. 4C). However, the adhesive-treated group expressed wider
corneal scars in contrast with the suture treated group, which could
inﬂuence visual acuteness. This may originate from an insuﬃcient
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cohesiveness of the adhesive to keep the edges of the wound closed [2].
In addition, this particular dendrimer-based adhesive required argon-
laser radiation to induce eﬀective crosslinking between dendrimers and
cornea, which may add cost and complexity to the surgical procedure
and could lead to possible side eﬀects.
Similar to linear PEG-based adhesives, dendritic macromolecules
can also be functionalized with nucleophilic groups, which subse-
quently react with another counterpart that has electrophilic moieties.
For example, the rapid formation of a thiazolidine bond between the
macromolecules with the aldehyde terminal groups and a counterpart
with the 1,2-aminothiol moieties in cysteine residues at room tem-
perature formed crosslinked hydrogel networks that were stable for pH
values ranging from 3 to 9 [91]. In vitro studies showed that 5min after
applying PEG-dendritic adhesive (([G1]-PGLSA- MA)2-PEG)) to a 3-mm
corneal linear incision, the sealant tolerated higher pressures applied to
the wound (up to 184 ± 79mmHg) compared to the conventional
sutures (up to 54 ± 16mmHg) or self-sealed wounds (up to
24 ± 8mmHg) [98]. This adhesive was also used to seal LASIK ﬂaps
[100] and repair corneal lacerations [78].
In order to improve the long-term stability of dendritic bioadhe-
sives, Wathier et al. utilized another peptide ligation reaction, a pseu-
doproline formation, where a dendron with N-terminal cysteine moi-
eties was reacted with PEGs with terminal aldehyde-ester moieties to
create highly stable hydrogels [101]. Such hydrogels were optically
transparent and showed a very slow rate of degradation, with only 10%
weight loss in 6 months in a humidity chamber. The mechanical
properties of this hydrogel were found to be strongly dependent on
prepolymer concentrations. The compressive moduli for hydrogels
made from 20, 33, or 50% (w/w) prepolymer solutions were 200, 570,
and 850 kPa, respectively. In vitro application of the hydrogel into 8-
mm trephined central corneal laceration was shown to lower the
number of the sutures required to secure the autograft and increased
the leaking pressure from 13 ± 5mmHg (sutured group) to
63 ± 7mmHg (hydrogel applied to sutured wound). However, the
application of adhesives did not secure the autograft, indicating that the
hydrogel might lack suﬃcient adhesiveness and coherence.
Oelker et al. engineered aldehyde-terminated PEG precursors, in-
cluding PEG-butyraldehyde (B-Ald PEG), PEG-2-oxoethyl succinate (E-
Ald PEG), and PEG-propionaldehyde (P-Ald PEG) to increase the sta-
bility of dendrimer PEG-based adhesives [1,102]. The crosslinking re-
action occurred between amine functionalities of the cysteine moieties
of Lys 3 Cys4 dendron with P-Ald or B-Ald PEG, forming thiazolidine
bond, that were prone to hydrolysis. On the other hand, the reaction
between the Lys3Cys4 dendron and E-Ald PEG formed thiazolidine
bonds which could rearrange through O,N-acyl migration and generate
more stable pseudoproline bonds. These hydrogels could seal full
thickness central corneal lacerations of 4.1mm in an ex vivo model to
tolerate IOPs comparable to those treated with a single suture [102].
Dendrimers have also been used as crosslinker agents to form ad-
hesive hydrogels for ocular applications. Duan et al. developed col-
lagen-based scaﬀolds crosslinked with a dendrimer for cornea tissue
engineering [97]. They used a collagen solution and a G-2 poly-pro-
pyleneimine octaamine dendrimer to produce a highly crosslinked
collagen-based network. Compared to other crosslinking agents (i.e.,
glutaraldehyde and 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide
hydrochloride, EDC), the crosslinked dendrimer scaﬀolds exhibited
superior mechanical performance (Fig. 4Di) and supported HCEC pro-
liferation on their surface (Fig. 4Dii).
Dendrimer-based adhesives hold high promise as ophthalmic sea-
lants. Conceivably, these hyper-branched compounds can be tailored
and used for broad spectrum of applications. They can be also en-
gineered for the controlled release of diﬀerent compounds [90] (e.g.
antibiotics, growth factors, and chemical messengers) to promote tissue
healing. The complexity and high cost of synthesis of dendrimers may
be the most signiﬁcant obstacles that prevent their applications in a
clinical setting. Besides the high cost to synthesize such complex
dendritic materials, manipulation of these adhesives into injured eye
tissue can also be challenging during the surgery, as the mixing of two
components may lead to fast formation of covalent networks in a short
period.
3. Naturally derived polymer–based adhesive
3.1. Protein-based adhesives
The use of protein-based materials to repair ocular tissues has re-
cently gained signiﬁcant attention. So far, several natural proteins such
as ﬁbrin, collagen, gelatin, and silk [103], have been studied with the
aim of repairing or sealing ocular wounds. Some of these materials have
received FDA approval for use as tissue adhesives (but not speciﬁcally
for ophthalmological use), and some, mainly ﬁbrin-derived products,
have become well-established commercial products. Examples are
CryoSeal® (Thermogenesis, CA, USA), Tisseel and Artiss (Baxter, CA,
USA), Evicel® (Johnson & Johnson, NJ, USA), and BioGlue® (Kennesaw,
GA, USA) [10]. VitaGel (Orthovita, PA, USA), a system to prepare ﬁbrin
glue from the blood of the patient, has been recently approved and
launched. Many other protein-based sealants are still at the research
and development stage.
3.1.1. Fibrin and ﬁbrinogen-based adhesives
Fibrin sealants, or ﬁbrin glues, together with cyanoacrylate-based
adhesives, remain the most commonly used suture substitutes in oph-
thalmology. The rationale behind the use of ﬁbrin as sealant is to mimic
the biological process of ﬁbrin clot formation. Fibrin (from the Latin
word ﬁbra, ﬁber) is an elastic and ﬁlamentous protein produced from
ﬁbrinogen catalyzed by the enzyme thrombin. This reaction naturally
takes place in the last stage of the coagulation cascade, forming an
interacting ﬁbrous network or blood clot. Thrombin catalyzes the
conversion of ﬁbrinogen to ﬁbrin by cleavage of the peptides A and B in
the central ﬁbrinogen nodule in the presence of calcium ions (Fig. 5Ai)
[104,105]. The release of ﬁbrin peptide triggers protoﬁbril formation. A
series of electrostatic and conformational changes follows, enabling
polymerization of ﬁbrin molecules into long and highly branched ﬁbers,
which then aggregate laterally to form the ﬁnal shape of the ﬁbrin
[105]. The structure and function of ﬁbrin and ﬁbrinogen [106–109],
and the process of clot formation have been described in detail in lit-
erature (Fig. 5Aii) [110].
In general, ﬁbrin glues are complex formulations derived from
mammalian plasma (mainly human and bovine) that combine ﬁ-
brinogen (typically derived from human plasma) with thrombin (bo-
vine or recombinant) to form ﬁbrin clots. Fibrin clots, formed by adding
diﬀerent concentrations of thrombin solutions to puriﬁed ﬁbrinogen,
develop diﬀerent crosslinking densities as observed by SEM (Fig. 5Aiii).
In vivo studies on ﬁbrin adhesives have conﬁrmed their biocompat-
ibility, biodegradability, and re-absorbability [105,111]. The adhesive
strengths of ﬁbrin sealants, as measured by the lap shear method, range
from 1 kPa to 27.9 kPa as a function of ﬁbrin concentration (Fig. 5Aiv)
and gelation time. For example, a 7.2 mg/mL ﬁbrin glue rendered a clot
with an adhesive resistance of 1 kPa after gelation for 5min, whereas a
34.5 mg/mL ﬁbrin glue showed an enhanced resistance of 27.9 kPa at a
gelation time of 90min [112]. In general, the adhesive strengths of
ﬁbrin glues are lower than other crosslinked protein-based biomaterials
(Fig. 5Aiv) but are suﬃcient for a vast range of ocular applications.
The use of ﬁbrin to repair corneal injuries was ﬁrst reported in the
early 2000s. Today, its application has been well documented to solve
many ophthalmic surgical problems. For instance, Sharma et al. de-
monstrated that ﬁbrin glues can be eﬀective in healing some corneal
perforations [113]; however ﬁbrin based glues are notoriously poor in
adhering to wet surfaces. Fibrin glues also presented several advantages
in terms of accelerated speed of healing (1 week faster) and less corneal
vascularization when compared to cyanoacrylates glues. However,
compared to cyanoacrylates, ﬁbrin glues required a longer time to gel
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after application (2 or 3min) [113]. Similarly, Bahar et al. used a ﬁbrin-
based adhesive in place of sutures to treat rabbit's eyes following tra-
beculectomy (a routine procedure used to lower IOP in glaucoma pa-
tients) [114]. They recorded excellent biosafety and no sign of severe
adverse eﬀects from ﬁbrin glues when compared with sutures. Based on
these results, ﬁbrin glues were considered a useful substitute for scleral
and conjunctival wound closure procedures.
Fibrin-based glues have also been tested in the Pterygium surgery
for conjunctival auto-grafting [115–117]. In this context, ﬁbrin glues
were safe and patient friendly, with faster application than the use of
suture ﬁxation of grafts. Moreover, Kaufman et al. reported the sa-
tisfactory use of a ﬁbrin adhesive for scleral amniotic patch adhesion
and sutureless lamellar keratoplasty [68]. A ﬁbrin-based adhesive was
considered eﬀective for sealing of conjunctival and skin grafts, LASIK
ﬂaps, and clear cornea incisions (Fig. 5Av) [118]. Likewise, the com-
bined use of a ﬁbrin glue and amniotic membrane transplantation was
demonstrated as a safe and eﬀective method for repairing corneas with
perforations of around 2mm [119]. Complete re-epithelization was
reported after 15 days of the intervention, along with stable and healthy
tissue recovery after 195–325 days.
The combined use of ﬁbrin glues and stem cells has also been re-
ported as a tissue engineering strategy for the repair of corneal tissues
as an alternative to corneal transplantation [120–122]. For example,
Rama et al. successfully accomplished re-epithelialization in 14 out of
18 ocular burn patients using this strategy [120]. The epithelium of the
treated patients resumed a normal and transparent appearance after
one month of the intervention, and the corneal tissue was healthy and
stable after 12–27 months. Recently, the use of ﬁbrin glues for surgical
reconstruction of the ocular surface after tumor removal was also re-
ported [123]. These studies suggest future opportunities to further ex-
tend the scope of ﬁbrin-based adhesives in ocular applications.
Fibrin glues have found multiple niches of application as ocular
Fig. 5. Structure, properties, and applications of ﬁbrin- and albumin-based adhesives. (A) Mechanism of ﬁbrin clot formation: (i) Schematic representation of
the conversion from ﬁbrinogen to ﬁbrin and subsequent polymerization/crosslinking mechanisms [133], (ii) Fibrinogen structure and its thrombin‐mediated con-
version to ﬁbrin. Binding sites for the main molecular actors that participate in ﬁbrinogen functions are illustrated. Adapted from Mosesson et al. [109] with
permission from Wiley, copyright 2005, (iii) Fibrin clots resulting from the addition of thrombin (0.5–20 nM) solutions to ﬁbrinogen (2 mg/mL) as observed by SEM.
(Scale bar: 1 μm). Adapted from Wolberg et al. [110] with permission from Elsevier, copyright 2007, (iv) Comparison of adhesive strengths of photocrosslinked
porcine gelatin, photocrosslinked bovine ﬁbrinogen, and a commercial ﬁbrin tissue sealant (Tisseel). Adapted from Elvin et al. [137] with permission from Elsevier,
copyright 2010, (v) An application of ﬁbrin glue in ophthalmology. Left eye of an infant patient with an inferotemporal growth before surgery, graft after attachment
with ﬁbrin adhesive, and 10 weeks later. Adequate graft integration with no edema and minimum haze was observed. Adapted from Zhou et al. [118] with
permission from Healio, copyright 2016; (B) Albumin based adhesives: (i) The 3D structure of albumin; a globular protein abundantly present in animal serum, (ii)
Mechanism of crosslinking and tissue adhesion of BioGlue®, (iii) Schematic illustration of laser soldering using albumin-based solders. Adapted from Chao et al. [126]
with permission from Wiley, copyright 2003, (iv) Rat eyes glued with albumin soldering after corneal epithelium removal surgery, and (v) ex-vivo breaking strength
measure on mouse skin soldered with albumin-based solder. The ratio of protein to ﬂuorescent dye has a signiﬁcant eﬀect on breaking strength as measured by
tensiometer. Adapted from Khadem et al. [131] with permission from Wiley, copyright 2004.
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sealants; they are perceived by many surgeons to be an eﬀective al-
ternative for the treatment of ocular lacerations [104] due to their
practicality and clinical beneﬁts including fast and practically complete
re-adsorption. However, ﬁbrin-based adhesives still face some out-
standing challenges, mainly related to their batch-to-batch product
variations, the possible presence of viral contamination, and im-
munological problems when derived from animal sources. This last
issue has been addressed by the use of ﬁbrin glue prepared from au-
tologous blood [120]. However, the autologous approach itself presents
disadvantages in terms of cost, time, and reproducibility/consistency of
product properties.
3.1.2. Serum albumin-based adhesive
Albumin is another type of natural protein that has been widely
investigated for the development of tissue sealants. Serum albumin
(SA), the most abundant protein in mammalian blood, is a globular and
water-soluble protein with a molecular weight in the range of
66.5–65.0 kDa. Human serum albumin (HSA) is a 585 aminoacids
protein that contains 17 pairs of disulﬁde bridges and one free cysteine
[124]. The molecular 3D structure of HSA has also been resolved
(Fig. 5Bi) [125].
Albumin-based materials have been investigated for cornea repair
purposes. For example, BioGlue® (Cryoline Inc.) [10], a commercially
available albumin-based adhesive that approved as a sealant for cardiac
surgery by the FDA in 1999, has also been proposed to use for oph-
thalmic purposes. BioGlue® is a formulation that contains of 10% glu-
taraldehyde and 45% bovine serum albumin (BSA). Glutaraldehyde
promotes covalent bonds between the lysine residues of albumin and
the tissue, thus providing excellent mechanical properties (Fig. 5Bii)
[126]. However, several risks are associated with the use of this pro-
duct. First, unreacted glutaraldehyde can introduce toxicity [127]. The
SA (normally extracted from animal sources) may also present im-
munological risks. The use of recombinant versions of HSA (e.g. pro-
duced in Pichia pastoris) may help overcome safety concerns and
Fig. 6. Structure, properties, and applications of collagen and gelatin-based adhesives. (A) Collagen-based adhesives. (i) 3D structure of collagen; collagen
triple helix with sequence (POG)10, (ii) The top view of helical twist in the collagen structure. The top view of the T3-785 peptide (crystal structure), represents the
ﬁrst three POG triplets on each chain. Adapted from Bella [138] with permission from Portland Press, copyright 2016, (iii) Schematic representation of the me-
chanism of crosslinking of collagen (or gelatin) in the presence of transglutaminase. Transglutaminase enzyme forms amide bonds between the acyl groups in
glutamine and the amino groups in lysine present in the protein (collagen or gelatin) chains. Adapted from Zhao et al. [152] with permission from Elsevier, copyright
2016; (B) Collagen and vitrigels. (i) Schematic explanation of the eﬀect of vitriﬁcation temperature and time on the microstructure of collagen vitrigels. Insets are
SEM images of the corresponding collagen vitrigels. Adapted from Calderón-Colón et al. [151] with permission from Elsevier, copyright 2012, (ii) Rabbit eye model
with stromal wound treated with collagen vitrigel membrane and ﬁbrin glue. Adapted from Chae et al. [163] with permission from Wiley, copyright 2015. (C)
Gelatin-based adhesives. Optical coherence tomography (OCT) of a rabbit eye with retinal detachment treated (i) with gelatin or (ii) gelatin crosslinked with
transglutaminase as observed 3 days of application. Images of histology transversal cuts of (iii) untreated and (iv) treated eyes three days after treatment. Gelatin-
mTG adhesives tightly adhered to the retinal surface. Adapted from Yamamoto et al. [164] with permission from Springer, copyright 2013, (v) Transparency of
gelatin and atelocollagen ﬁlms after under wet conditions, (vi) Strain vs stress curves for diﬀerent gelatin hydrogel ﬁlms. Adapted from Watanabe et al. [170] with
permission from Mary Ann Liebert, copyright 2011.
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reduce batch-to-batch variability of albumin-based sealants [128,129].
In another study, Khadem et al. [130,131] used laser-crosslinkable
albumin-based formulations (laser soldering) to close cornea incisions.
These materials were formulated with BSA and two diﬀerent dyes
(chlorin-e6 and Janus Green) that could trigger crosslinking between
albumin in the glue and proteins in the ocular tissue upon photo-
dynamic activation using 665 nm laser (Fig. 5Biii). The adhesive was
applied to rat corneal incisions in vivo (Fig. 5Biv) and evaluated ex vivo
at diﬀerent times (1–14 days postmortem) to determine leakage pres-
sure and inﬂammation by histological analysis. One day after applica-
tion, the average leakage pressures were 430mmHg for the adhesive
made from BSA/Janus Green glue, which was higher than that of the
BSA/chlorin-e6 glue (357mmHg). Likewise, the breaking strength was
signiﬁcantly higher for the BSA/Janus Green glue (ca. 3.5 N) than for its
chlorin-e6 counterpart (ca. 2.5 N) when the materials were used to glue
rat skin and then submitted to tensile tests (Fig. 5Bv).
Recently, the eﬀective application of temperature control and
radiometry during laser soldering to treat corneal cuts has been re-
ported [132,133]. For example, Tal et al. demonstrated the application
of a temperature-controlled CO2 laser soldering system (power density
of 16W/cm2; 65 °C) using a BSA-based solder (47%) for corneal cut
closure [132]. The authors used pigs as the animal model and demon-
strated that the soldered corneas had milder stromal inﬂammation, less
neovascularization, and a higher level of re-epithelization than sutured
controls.
The incorporation of nanoparticles (NPs) in BSA has also been re-
ported to produce laser solders with enhanced bioadhesive performance
[134,135]. However, the use of these materials has not yet reported for
ophthalmic purposes. The mechanism underlying the laser soldering of
protein-based adhesives is not fully understood; mechanistic explana-
tions include thermal remodeling, protein denaturation, and protein
degradation, among others [136].
Altogether, the experimental evidence suggests that albumin-based
adhesives could serve as a suitable family of materials for ophthalmic
use. However, some challenges to overcome remain the batch-to-batch
product variations, and biosafety issues related to albumin obtained
from animal sources.
3.1.3. Collagen and gelatin-based adhesives
Collagen is the most abundant protein in mammals, and the main
structural protein in the extracellular microenvironment of the con-
nective tissues in animals. Not surprisingly, collagen-based materials
have been investigated for the development of novel corneal adhesives.
The highly complex structure of collagen has been, and continues to be,
an important subject of study (Fig. 6Ai-ii) [138]. Collagen is also
naturally present in corneal stroma. It imparts very important func-
tional properties to the cornea, including transparency and mechanical
strength [139]. The architecture and properties of collagen ﬁbrils have
been extensively studied elsewhere [139–141].
The natural chemical properties of the endogenous corneal collagen
have been exploited to correct keratoconus, a progressive eye disease
that involves the bulging of the cornea into a cone shape. Since the
early 90s, multiple reports have described diﬀerent strategies to induce
the crosslinking of the collagen originally presented in the cornea using
riboﬂavin and UV-A irradiation. The eﬀectiveness and safety of this
general approach have been validated by several studies [142–145].
Avedro, Inc. was granted FDA approval for this technique to treat
progressive keratoconus [146]. Later, the crosslinking procedure was
accelerated from 1 h to 3min by increasing the UV-A power. Recently,
Richoz et al. observed that the process of corneal collagen crosslinking
with riboﬂavin and UV light was oxygen dependent. Stronger cross-
linking was achieved under high oxygen tensions [147].
Exogenous sources of collagens (animal-derived and recombinant
collagen) have also been formulated in diﬀerent ways to produce
ophthalmic glues, e.g. ﬁlms or coatings [8,9,148], soldering [149],
hydrogels [150], and vitrigels [151]. Collagen-coated surfaces exhibit
appropriate as substrates for the adhesion and proliferation of corneal
epithelial cells. For instance, Kim et al. documented the use of trans-
parent poly (lactic-co-glycolic acid) (PLGA) ﬁlms coated with collagen
type I as a substratum for corneal tissue regeneration or inclusively as a
material for artiﬁcial corneas for transplantation [148]. The authors
demonstrated that primary corneal rabbit cells adhered, grew, and re-
tained their expected cell morphology and phenotype when seeded in
vitro on PLGA ﬁlms coated with collagen, whereas they did not show
these features when grown on pristine PLGA ﬁlms without coating.
Collagen has been formulated as a soldering material (laser-cross-
linkable) for corneal repair in a few reports [144,149]. For example,
Noguera et al. developed a collagen-based, laser-activated solder to
repair corneal wounds [149]. Solder patches, fabricated by casting a
concentrated solution of chemically modiﬁed collagen, followed by
freeze drying, were used to repair incisions of 2 and 3mm made ex vivo
on rabbit corneas. The chemically modiﬁed collagen, used to fabricate
the patches was prepared by reacting bovine or porcine collagen I with
glutaric anhydride. The free amines within the collagen chain reacted
with the anhydride to produce a material that underwent a thermal
transition between 40 to 45 °C and had a suﬃcient number of car-
boxylic groups to crosslink with the cornea tissue upon exposure to low
intensity laser light. The use of soldering patches rendered better results
than conventional suturing. The IOP (125.16 ± 9.85mmHg) was sig-
niﬁcantly higher in eyes treated with solder ﬁlms than in sutured eyes
(33.44 ± 9.38mmHg).
Other collagen-based adhesives used for ocular repair include col-
lagen with transglutaminase, which yields a crosslinked network by
forming bonds between amine and acyl groups [152] (Fig. 6Aiii), col-
lagen-immobilized vinyl alcohol scaﬀolds to support corneal epithelium
growth [153], collagen-based hydrogel scaﬀolds [150,154], PEG-sta-
bilized carbodiimide crosslinked collagen–chitosan hydrogels [155],
alginate microsphere-collagen hydrogels [156], recombinant collagen
versions [157], collagen–phosphorylcholine interpenetrating network
hydrogels [158], collagen- and glycopolymer-based hydrogel [159],
and collagen hydrogels crosslinked with carbodiimides [160].
In the last decade, collagen vitrigels (CV) have been also studied as
scaﬀolds for diﬀerent tissues, including eye. Collagen vitrigels are thin
transparent membranes made of highly compacted collagen I ﬁbrils that
resemble the natural architecture of collagen in the cornea [158].
Several reports have demonstrated that these materials are biocompa-
tible and have good mechanical, optical, and permeability properties
[158,160,161]. CVs are made by a three-step process: (1) gelation, (2)
vitriﬁcation, and (3) rehydration. During the vitriﬁcation process, the
collagen ﬁbrils of the hydrogel compact together forming a dense net-
work, rendering a rigid material, which is later rehydrated to obtain a
soft and strong membrane. An optimized process to produce CVs with
improved characteristics and shorter preparation/vitriﬁcation time was
reported by Calderón-Colón et al. (Fig. 6Bi) [151]. The authors tested
conditions that produced CVs with a denaturation temperature of 54 °C,
which made them suitable for use at body temperature without risk of
degradation. The vitriﬁcation conditions, including temperature, re-
lative humidity (RH), and the vitriﬁcation time, had a clear inﬂuence
on the collagen ﬁber self-assembly process and the vitrigel micro-
structure, which subsequently inﬂuenced the mechanical, thermal, and
optical properties of the resulting CVs. Low vitriﬁcation temperature
and short vitriﬁcation time resulted in a less compact microstructure.
The collagen ﬁbrils formed a tighter and more organized microstructure
at higher temperature and longer vitriﬁcation time (Fig. 6Bi). For in-
stance, a 0.05mm CV vitriﬁed at 10 °C with 20% RH for half a week
showed an open/loose mesh microstructure that exhibited an ultimate
tensile strength of 669 kPa and a 71% transmittance. By contrast, a CV
vitriﬁed at 40 °C with 40% RH for 1 week showed a tighter and ﬁner
microstructure that exhibited an ultimate tensile strength of 8174 kPa
and an 84% transmittance. Guo et al. studied the eﬀects of diﬀerent
vitriﬁcation conditions, including temperature, temperature changes,
relative humidity, and vitriﬁcation time on the ﬁnal properties of CV
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membranes [162]. The process variables signiﬁcantly inﬂuenced the
nano-architecture of the membranes. Consistently, the authors observed
that a high temperature (39 °C) and long vitriﬁcation time (8 weeks)
resulted in CVs with highly dense structure (80 nm ﬁbril-ﬁbril space). In
turn, the nano-architecture of CV membrane has a strong eﬀect on the
morphology and phenotype of keratocytes cultured on these CV mem-
branes. When compared with growth on regular culture plates, kera-
tocytes cultured on CVs exhibited a higher degree of branching with a
longer average branch length [162]. In vitro studies with primary cell
lines also suggested that CV membranes were potential candidates for
reconstruction of the endothelial, epithelial, and stromal layers of the
cornea [161].
Chae et al. evaluated the combined use of CV and chondroitin sul-
fate hydrogels to repair severe eye injuries in the battleﬁeld. Treated
injuries ranged from 3 to 8mm in size from the cornea to the scleral
region [9]. The authors used a “patch and glue system”, consisting of a
pre-shaped (ﬂat or curved) CV and a chondroitin sulfate adhesive hy-
drogel. Mechanical burst tests in porcine eyes, which consisted of in-
jecting saline solution into the treated eyes at 20 mL/h until a 35mmHg
IOP was reached, revealed that the combined use of CV membranes and
chondroitin sulfate glue was suitable for repairing wounds as large as
6mm in superﬁcial injuries and 8mm in a deeper region (scleral). The
glue itself (without the patch) was only able to repair superﬁcial la-
cerations of 3mm and lacerations at the scleral region of 4mm before
burst tests failed.
Chae et al. reported the use of CVs along with ﬁbrin glue to repair
corneas in limbal stem cell deﬁciency (LSCD) and stromal wound [163].
Both clinical conditions were induced in rabbits by keratectomy and by
chemical burning, followed by corneal epithelium scraping, respec-
tively. The application of CV glued with ﬁbrin, CV with human limbal
epithelial cells (hLEC), and ﬁbrin glue only, were studied as diﬀerent
strategies to repair the tissue. The most successful results were observed
with the CV and ﬁbrin glue combination to repair stromal wounds, and
CV with hLEC to treat LSCD (Fig. 6Bii). In particular, the combined
application of CV with ﬁbrin glue allowed healthy regeneration of the
corneal epithelium. In contrast, ﬁbrin alone resulted in a hypertrophied
corneal epithelium. Similarly, the strategy of using CV with hLEC al-
lowed the growth of healthy and transparent epithelium, with low
vascularization and inﬂammation, whereas vascularization and in-
ﬂammation were signiﬁcant in the control (untreated eyes) [163].
Gelatin is another promising candidate material for ophthalmic
applications since it is derived from a partial hydrolysis of collagen,
which is an endogenous component in the cornea. Gelatin is a water-
soluble polypeptide mixture that can be crosslinked by diﬀerent
methods to produce adhesives and hydrogels with suitable properties
for ocular tissue repair. Gelatin-microbial transglutaminase (gelatin-
mTG) has been suggested as a suitable material for adhesive ophthalmic
applications (Fig. 6Aiii) [164–166]. Yamamoto et al. inferred vi-
trectomy with artiﬁcial posterior vitreous detachment (PVD) followed
by retinal tear and detachment to rabbits [164]. Then, the authors used
a Gelatin-mTG complex to treat the animals. After administration, the
material adhered and sealed retinal tears for several days without no-
ticeable inﬂammatory reaction (Fig. 6Ci-iv). Chen et al. conducted
additional in vitro adhesion studies on bovine retinal tissue using a si-
milar gelatin-mTG biomimetic material and reported lap shear strength
at wet conditions ranging from 15 to 45 kPa [166]. These values were
comparable to those reported for other soft-tissue glues, suggesting that
mTG-crosslinked gelatin may be a suitable adhesive for ophthalmic
applications. Sealants based on chemically modiﬁed gelatin, e.g. gelatin
methacryloyl (GelMA) [167–169], are emerging players in eye tissue
repair applications [170,171]. For example, GelMA membrane cross-
linked by dehydration (160 °C for 6–48 h at 0.01 Torr) exhibited a
comparable or superior performance versus commercially available
collagen sheets (KOKEN Co. Ltd., Tokyo) as corneal endothelial cell
carriers for corneal transplantation [170]. Gelatin sheets outperformed
collagen sheets in many characteristics such as permeability, ﬂexibility,
transparency (Fig. 6Cv), and elasticity. However, the toughness of ge-
latin formulations was lower than those measured for atelocollagen
(enzymatically treated collagen) membranes (Fig. 6Cvi). A healthy and
ordered monolayer of corneal endothelial cells, attached to the gelatin
hydrogel membranes, exhibited normal expression levels of sodium and
calcium ATPases, ZO-1, and N-cadherin.
3.2. Polysaccharide-based adhesives
Polysaccharides represent various biopolymers that are ubiquitously
found in living organisms. Polysaccharides are linear or branched
polymers that are constructed from diﬀerent monosaccharides as their
structural building blocks. The combination of sugar monomers, var-
iations in functional groups, and selection of chemical linkages oﬀer
nearly unlimited deviations in chemical structures and biochemical
properties of polysaccharides species. Common polysaccharide pro-
ducts extracted from animals or plants are regarded as biocompatible
and biodegradable, therefore leading to widespread applications of
polysaccharides in pharmaceutical, cosmetic, food, and biomedical in-
dustries. In general, polysaccharide-based tissue adhesives are hydro-
gels made from chemically-modiﬁed, water-soluble polysaccharides.
Depending on the selection of polysaccharides and the desired way of
delivery, crosslinking mechanisms of polysaccharide-based hydrogels
may vary. In particular, researchers have focused on three speciﬁc kinds
of natural polysaccharides to develop tissue adhesives for ophthalmic
surgery applications, namely, chondroitin sulfate, dextran, and hya-
luronic acid (HA), which will be summarized in the following sections.
3.2.1. Chondroitin-based adhesives
Chondroitin sulfate is a linear sulfated glycosaminoglycan com-
posed of alternating N-acetylgalactosamine and glucuronic acid units.
Introduction of the sulfate groups can happen at diﬀerent sites along
the chain with varied degree of functionalization. In the living body,
chondroitin sulfate is an important component of the cartilage tissues.
The long-term biosafety of chondroitin sulfate has been well docu-
mented. As a result, it is widely used as a dietary supplement to prevent
and treat osteoarthritis, although its medical eﬀects are not clinically
approved.
Several diﬀerent chemical modiﬁcation methods have been re-
ported to prepare chondroitin sulfate-based hydrogels targeting at dif-
ferent biomedical applications. For example, Li et al. reported the mild
reaction between chondroitin sulfate and glycidyl methacrylate to
synthesize a photocrosslinkable, methacrylated chondroitin sulfate de-
rivative [172]. By changing parameters such as degree of functionali-
zation, prepolymer concentration, and crosslinking conditions, chon-
droitin sulfate hydrogels with tunable physical properties could be
fabricated by facile photopolymerization techniques. Moreover, cyto-
compatibility of the hydrogel was established by encapsulation of
chondrocytes inside the hydrogels, which remained viable and meta-
bolically active, thus suggesting their potential applications in cartilage
tissue engineering [114].
Reyes et al. reported another crosslinking chemistry based on the
controlled oxidation of chondroitin sulfate by sodium periodate to in-
troduce reactive aldehyde groups, which form crosslinked networks
with amine groups by formation of Schiﬀ base linkages (Fig. 7A) [174].
The usage of chondroitin sulfate hydrogel, as an adhesive layer between
the implanted biomaterials and native cartilage tissues, showed strong
adhesion and stable integration (over ﬁve weeks in vivo) to repair
wounded cartilage tissues [175]. NHS-activated chondroitin sulfate
derivative has also been reported by Strehin et al., which could react
with amine-bearing PEG crosslinkers to form stable hydrogels with
amide linages (Fig. 7A). In addition, the NHS-ester groups could also
react with amine groups on tissue surfaces to enhance adhesion
[173,176].
An ophthalmic adhesive based on chondroitin sulfate aldehyde and
polyvinyl alcohol covinylamine (PVA-A) was formulated to seal corneal
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incisions [174]. As discussed above, the aldehyde groups can react with
amine groups in PVA-A to generate hydrogels in situ. The eﬃcacy of this
chondroitin sulfate-based adhesive was compared with standard suture
techniques to seal uniplanar, clear corneal incisions (3 mm) in an ex
vivo rabbit model [174]. The maximum IOPs before wound leakage of
the sealed or sutured eyes were evaluated and compared to reveal the
eﬀectiveness of the adhesive. The mean IOP observed in glued eyes was
101.4 ± 3.2mmHg (n= 8), which was signiﬁcantly higher than those
values from either single-suture or three-suture subgroups (26.4 ± 6.0
and 44.3 ± 8.2mmHg, respectively). This indicates that the chon-
droitin sulfate-based adhesive is a promising material to replace sutures
as a corneal incision sealant [174]. Another chondroitin sulfate based
adhesive was also tested in the microkeratome-assisted posterior la-
mellar keratoplasty setup to evaluate the astigmatic change and the
stability of the graft stability when using the tissue adhesive in the
modiﬁed procedure [177]. The standard suture technique was used as
control. A partial ﬂap keratectomy (300-μm-thick) was conducted ex
vivo in corneoscleral rims of a human donor with a 6.25-mm trephi-
nation, which was subsequently ﬁxed with either ﬁve interrupted su-
tures or the chondroitin sulfate-based glue [177]. It was revealed that
both techniques showed comparable mean astigmatic changes
(3.08 ± 0.84 D for sutures vs. 1.13 ± 0.55 D for the adhesive) and
similar mean resistant pressures (95.68 ± 27.38mmHg for suture vs.
82.45 ± 18.40mmHg for the adhesive). The results indicated that
these suture-less alternatives are promising for clinical treatment of
corneal endothelial disorders [177].
The ability to seal small corneal incisions of the NHS-activated
chondroitin sulfate/amine-PEG adhesive was also accessed in a swine
model (Fig. 7B). Tested on a 6.0-mm defect made in the swine cornea,
this chondroitin sulfate-based adhesive was able to restore maximum
IOP greater than 200mmHg. The adhesive was also non-toxic to major
types of cells found in the cornea. Moreover, histological results
i ii iii iv
Fig. 7. Examples of polysaccharide-based adhesives. (A) Commonly used chemical crosslinking mechanisms for chondroitin sulfate-based hydrogels. (B)
Application of NHS-modiﬁed chondroitin sulfate/amine PEG sealants in a swine eye model, (i) A 6.0 mm defect was made in the cornea with a trephine, (ii) an
incision was made to get a ﬂap, (iii) the sealant was applied to glue the ﬂap to the stroma, (iv) the ﬂap was tightly adhered 2 weeks after surgery. Adapted from
Strehin et al. [173] with permission from Elsevier, copyright 2009. (C) Schematic illustration of the partial oxidation of dextran and the formatting mechanism of
hydrogels crosslinked by amine-containing crosslinkers. (D) Schematic illustration of the methacrylation and photocrosslinking reactions of HA-based sealant.
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demonstrated minimal inﬂammatory response and no scar formation
after two weeks of application [173,176]. Taken together, these results
conﬁrmed that chondroitin sulfate-based adhesives are promising can-
didates for ophthalmic applications. The excellent biosafety of chon-
droitin sulfate, superior surgical performance, and the versatile chem-
istry for tailored properties of the adhesives are the desirable
advantages of chondroitin sulfate-based tissue adhesives. However,
since the most common source for producing chondroitin sulfate is from
animal tissues, concerns associated with long-term biosafety and batch-
to-batch variation should be noted for future clinical applications.
3.2.2. Dextran-based adhesives
Dextran is a complex polysaccharide with certain branches along
the linear chain. The main linear section is composed of glucose linked
by alpha-1,6 bonds. As dextran lacks multiple reactive substitutional
groups (e.g. amine groups and carboxylic acid groups), the availability
of functional groups for chemical modiﬁcations are limited. The most
common chemical modiﬁcation strategy on dextran is based on a con-
trolled oxidation reaction by periodate, similar to that of chondroitin
sulfate (Fig. 7C). Subsequently, the oxidized aldehyde-containing dex-
tran derivatives can react with amine-bearing crosslinkers to form hy-
drogels via the imine linkage formation. Other strategies include pho-
tocrosslinkable dextran derivatives with methacrylate groups [178] and
enzyme-responsive dextran materials with tyramine motifs [179].
Araki et al. developed a dextran-based tissue sealant by reacting
aldehyde-bearing dextran with ε-poly (L-lysine) [180,181]. The ad-
hesive properties of this sealant were ﬁrst evaluated in an in vivo lung
model using ﬁbrin glues as the controls. Biodegradability and bio-
compatibility of this adhesive were also evaluated in a dog model which
showed the potential clinical application of the tissue adhesive
[180,181]. Later, this aldehyde dextran/ε-poly (L-lysine) was applied as
the adhesive in suture-less amniotic membrane transplantation to ﬁx
the membrane to the ocular surface in a rabbit model [182]. In vivo
experiment results showed that the dextran-based adhesive could
tightly ﬁx the membrane to ocular surface, did not interfere with the
cell growth, and promoted tissue regeneration. Moreover, the adhesive
material could be degraded in 4 weeks in vivo, therefore providing a
valuable alternative to replace sutures and reduce the risks of suture-
related infection, scarring, and damage to surrounding tissues [182].
Dextran-based ophthalmic adhesives were also tested in a suture-
less automated lamellar therapeutic keratoplasty setup to evaluate their
ability to ﬁx grafts [183]. A three-month in vivo study in a rabbit model
proved that grafts sealed to the cornea remained attached and clear for
90 days. Epithelialization on the glued graft was observed within 7 days
with no indication of apparent signs for inﬂammation or scarring. This
study demonstrated that dextran-based adhesives could be an alter-
native technique in treating corneal diseases [183]. Bhatia et al.
documented the use of a similar dextran-based tissue adhesive con-
taining a crosslinker consisting of an 8-arm amine-PEG derivative
[184]. The cytotoxicity of this adhesive was ﬁrst tested in vitro using
J774 macrophage cells and 3T3 ﬁbroblast cells. Results conﬁrmed that
the dextran-PEG adhesive was not toxic to the cells and did not induce a
signiﬁcant inﬂammatory cell activation (J774 macrophages did not
release inﬂammatory markers) [184]. The authors further evaluated the
ex vivo sealing ability of the adhesive on 5mm corneal incisions in a
rabbit model. By applying 40 μL of the adhesive prepolymer solution,
the sealed incision could resist pressures up to 557 ± 23mmHg, pro-
viding promising implications that these could be used to replace suture
procedures in closing corneal wounds [185]. The authors later reported
a delivery device to reduce the volume of adhesive needed for sealing a
3.2 mm corneal incision to less than 2 μL. The sealed corneal could
resist leakage pressure of at least 120mmHg for at least 5 days post
application [186].
The dextran-based ophthalmic adhesives have been the subject of
multiple in vitro and in vivo studies to demonstrate their excellent per-
formance in closing corneal wounds and ﬁxing grafts to the ocular
surfaces. Their biocompatibility has been examined by histological
analysis to prove that the adhesives did not induce inﬂammation nor
interfere with tissue regeneration. However, dextran-based adhesives
oﬀer less potential to tailor their properties in comparison to other
molecules (i.e., PEG-based, dendrimer-based and chondroitin-based
adhesives) because of their scarcity of functional groups available for
chemical modiﬁcations.
3.2.3. Hyaluronic acid-based adhesive
HA is a polysaccharide composed of 2-acetamide-2-deoxy-D-glucose
and D-glucuronic acid units. HA is a natural component of the gel ﬁlling
in eyes and has also been correlated with cellular migration behavior in
the wound healing process. As a result, HA is a very appealing material
for the development of tissue adhesives or scaﬀolds for tissue en-
gineering applications. For ocular applications, HA-based adhesives can
be synthesized based on a photocrosslinkable derivative.
Miki et al. reported the chemical modiﬁcation of HA with me-
thacrylic anhydride to introduce methacrylate groups onto the poly-
saccharide backbone (Fig. 7D) [8]. The resulting methacrylated hya-
luronic acid (HAMA) was combined with the ethyl eosin and
triethanolamine photoinitiator system to formulate the photo-
polymerizable HA-based adhesive. A low-density argon laser (514 nm,
200mW) was used to convert the viscous liquid prepolymer solution
into a crosslinked transparent hydrogel network. In an in vivo rabbit
model, the prepolymer solution was delivered to the 3mm corneal la-
ceration and polymerized in situ to seal the incision. No leakage was
observed in 37 out of 38 rabbit eyes and the seal lasted for at least 7
days. The HA-based adhesive did not show in vivo cytotoxicity nor in-
ﬂammatory responses. Moreover, the deposition of new extracellular
matrix (ECM) and the proliferation of stromal cells at wound sites were
observed at day 7 post-surgery, suggesting rapid tissue regeneration of
the sealed cornea. The measured IOP values for this HA-based ocular
adhesive were 5–10mmHg by day 1 and increased to 10–15mmHg by
day 7. This study suggested that HA-based adhesives could also be
developed for various ocular applications [8].
Despite the excellent biosafety and reported good results of HA-
based adhesives, the use of photopolymerization technique in oph-
thalmic applications might raise concerns about light-induced tissue
damage or about the relative complex experimental setups to introduce
the light source to the operating room. Future developments to in-
troduce other crosslinking mechanisms to hyaluronic acid-based hy-
drogels might expand the applications of these polysaccharides in
ophthalmic adhesives.
So far, we have presented and discussed the characteristics, ad-
vantages and disadvantages of a spectrum of eye adhesives. Among
several characterization methods, the leakage pressure measured on ex
vivo eyes, have been used by several authors as a useful parameter to
compare the performance of ocular sealants (Table 1). Other important
parameters frequently reported include: cytotoxicity, inﬂammatory re-
sponse, tissue regeneration, biodegradability, transparency, micro-
structure and other mechanical properties (in addition to leakage
pressure). Patient comfort is one of the main aims of developing and
using ocular adhesives, however, this is a “parameter” that is elusive to
quantitation and has been less frequently reported in literature, except
for cyanoacrylates or products already commercially available. Novel
promising alternatives are being developed today, and in the years to
come, they will hit the marketplace yielding beneﬁts to physicians and
patients. Some of these new materials are more than simply adhesives;
they are engineered to provide beneﬁts that go beyond adhering tissues
and provide with additional features or “upgrades” (i.e., drug delivery
or sensing capabilities) to the conventional concept of ocular adhesive.
4. Adhesives for ocular drug delivery
The eye has various protective mechanisms, such as tear production,
tear ﬂow, and blinking, that promote rapid drainage of the drug via the
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nasolacrimal duct. Therefore, conventional strategies for ocular drug
delivery, including the application of solutions and suspensions, can be
partially ineﬀective since liquids can be readily washed from cornea
through natural processes. Ointments have been used to deliver ocular
drugs and overcome these challenges, but they blur the vision by
changing the tear's refractive index [189]. To address these limitations,
drug delivery components have been incorporated into bioadhesives
and soft contact lenses to extend the residence time of active in-
gredients in the eye [190]. Here, we review bioadhesives designed for
various ocular applications, ranging from drug delivery to “wound-
ﬁlling” where signiﬁcant stromal loss in the cornea puts the eye at risk
of perforation and thus needs to be closed for securing the anatomical
integrity of the eye as well as promoting tissue healing and regenera-
tion. It is important to note that some bioadhesives have inherent an-
tibacterial properties, while others are granted therapeutic or protective
properties by impregnating drugs in the bioadhesive or incorporating
drug-loaded constructs, such as NPs and microspheres [189,190].
Giano et al. used a novel syringe-injectable, an inherently anti-
bacterial bioadhesive hydrogel for wound-ﬁlling applications [190].
The bioadhesive had antibacterial properties against both Gram-nega-
tive and Gram-positive bacteria, without harming human erythrocytes.
This bioadhesive was developed by mixing branched polyethylenimine
and polydextran aldehyde and achieved a maximum adhesive stress of
2.8 kPa. Using a murine infection model, it was shown that this ad-
hesive could kill Streptococcus pyogenes presented on the bioadhesive's
surface, without inducing inﬂammation. In addition, the adhesive was
investigated through a cecal ligation and puncture model and was
found to inhibit sepsis [190].
One of the ﬁrst examples of a drug-impregnated bioadhesive was
provided by Hui and Robinson [191]. They synthetized a drug-loaded
polymeric adhesive, in which the polymer consisted of acrylic acid
crosslinked with 2,5-dimethyl-1,5-hexadiene and progesterone was
used as a drug model. The progesterone was incorporated to the system
during polymer synthesis. The material was swollen in water to form a
tridimensional matrix poly (acrylic acid hydrogel) with an entrapped
drug (progesterone) which was dissolved by the water within the hy-
drogel and could be released by diﬀusion. The swollen poly (acrylic
acid) adhesive exhibited good bioadhesion to rabbit conjunctival
membranes (231 ± 44 dyn/cm2). In vitro release studies showed that
the system did not oﬀer enough barrier opposition to control the release
rate of the entrapped progesterone. However, bioavailability studies
using albino rabbits demonstrated a statistically signiﬁcant increase of
drug concentration in the aqueous humor in the animals that received
the drug through the bioadhesive as compared to the ones that received
it in suspension (drops) [191].
Chae et al. investigated the combination of a chondroitin sulfate-
polyethylene glycol (CS-PEG) adhesive and a corneal-shaped, collagen-
based CV membrane as a means of treating penetrative ocular injuries
on the battleﬁeld [9]. The corneal-shaped CV successfully matched the
corneal contour without wrinkling. A vancomycin-loaded CS-PEG
component, used to control release antibiotics, shown to inhibit Sta-
phylococcus infection for 9 days. The CS-PEG was found to treat wounds
(5-mm to 6-mm length) in the cornea and corneoscleral regions.
However, the combination of CS-PEG and CV was required to treat
larger wounds [9]. In another study, it was shown that silver NPs can
reduce the growth of bacteria by at least one order of magnitude and
enhance mechanical strength of the ocular adhesives [192]. The
greatest mechanical strength was observed with adhesives doped 10 nm
silver NPs at a concentration of 10 μg/mL; the force required to disrupt
these adhesive bonds was approximately 22 kPa.
Drug delivery systems can be also designed by ﬁrst incorporating
drugs into NPs and then combining them with hydrogel prepolymer
solutions. Chitosan and sodium alginate are natural and biodegradable
polymers that have been commonly used in the preparation of NPs for
ophthalmic formulations. Chitosan has unique properties such as
bioadhesiveness, biocompatibility, biodegradability, and inherent an-
tibacterial activity, which together make it an attractive mucoadhesive
polymer [193]. In a study by Motwani et al. [196], chitosan and sodium
alginate NPs were explored for ophthalmic delivery of the antibiotic
gatiﬂoxacin for a prolonged time period [196]. Gatiﬂoxacin, an anti-
bacterial agent used to treat ocular infections, was released in vitro in a
sustained manner for 24 h, as compared with conventional eye drops
which fail to achieve sustained drug release and often require a high
dosing frequency. In another study, Ibrahim et al. used an adhesive that
contained NPs of either chitosan or alginate, loaded with brimonidine
(Celecoxib™), for the management of glaucoma (Fig. 8A) [193]. The
alginate NP were incorporated into a hydrogel formulation that con-
sisted of in situ gelling system triggered by temperature and exhibited
sustained release in vitro (Fig. 8Ai-ii). Additionally, an in vivo study in
mice revealed that the IOP-lowering eﬀect of the formulation lasted for
Table 1
Summary of reported ocular adhesives and their eﬃciency in sealing an ocular leak.
Category Leakage pressure (mmHg) Wound type Ex vivo model Refs
Octyl 2-cyanoacrylate 55.13 ± 10.46 5.2-mm full-thickness central corneal lacerations on porcine porcine [187]
Nylon 10-0 suture 52.37 ± 7.16
n-Butyl cyanoacrylate 51.2 ± 15.0 2.5-mm uniplanar corneal incision rabbit [53]
Methoxypropyl cyanoacrylate 65.2 ± 14.5
Fibrin glue 17.5 ± 5.2
Nylon 10-0 suture 15.6 ± 5.2
PEG (3400)-DA with ([G2]- (Lys)3 -Cys4) 184 ± 79 3-mm clear corneal linear incision chicken [91]
Suture group 54 ± 16
PEG (3400)-DA with ([G2]- (Lys)3 -Cys4) 142 ± 22 2.75-mm clear corneal cataract incisions Human [188]
Non-sealed wound 77 ± 14
[G1]-PGLSA-MA)2 -PEG 171 ± 44 4.1-mm linear laceration chicken [78]
Suture group 90 ± 18
[G1]-PGLSA-MA)2 -PEG 109.6 ± 82.7 4.1-mm linear laceration Human [98]
Suture group 78.7 ± 27.8
CS-PEG + CV 35 22-mm linear laceration Porcine [9]
BSA-ce6 357 ± 25 6-mm full-thickness central corneal incision Rat [131]
BSA-JG 430 ± 36
Non-sealed group 193 ± 6
Laser-soldering collagen patch 3.62 ± 3.09 3.0-mm uniplanar peripheral oblique corneal wound Rabbit [149]
Suture group 33.44 ± 9.38
Non-sealed group 125.2 ± 9.85
Laser-soldering collagen patch 101.4 ± 29.92 2.85-mm straight keratome
Suture group 82.7 ± 6.55
Non-sealed group 1.7 ± 0.13
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more than 25 h after application and thus achieved a sustained eﬀect
that was comparable to that of the commercially available Alphagan P
eye drops (Fig. 8Aiii) [193].
Zhang et al. loaded ciproﬂoxacin, a wide spectrum antibiotic, into
PLGA NPs that were subsequently embedded into a 3D adhesive hy-
drogel [194]. The NP-gel was created by mixing the NPs with dopamine
methacrylamide (DMA; adhesive agent and monomer), acrylamide (a
monomer), poly (ethylene glycol) methacrylate (PEG-MA) (crosslinker),
and lithium phenyl-2,4,6-trimethylbenzoylphosphinate (photoinitiator)
(Fig. 8Bi). This hybrid system allowed for prolonged antibiotic release
(Fig. 8Bii) while achieving reliable adhesion under high shear stress
(3.4 Pa). The adhesion properties of the NP-gel, under ﬂow conditions,
on diﬀerent biological surfaces (mouse skin tissue, mammalian cell
monolayers, and bacterial ﬁlms) were evaluated and found to be su-
perior in response than the gel without DMA. For example, in a peeling
test where two layers of mouse skin were glued with 100 μL of NP-gel
adhesive, a force of around 0.3 N was required to separate the skin
layers, as opposed to the 0.03 N required for the control, a non-adhesive
NP-gel. The viscoelasticity and adhesion property could be tuned with
regard to the shear stresses present in diﬀerent conditions. Additionally,
the hybrid composition was found to inhibit the development of a
bioﬁlm of E. coli under ﬂow conditions in vitro (Fig. 8Biii) [194].
Song et al. explored the potential of drug-loaded nanocarriers with a
rough surface, inspired in the morphology of pollen grains, to enhance
adhesion to bacteria and achieve long-term bacterial inhibition
(Fig. 8Ci) [195]. The rough mesophorous silica hollow spheres were
loaded with lysozyme (an antibacterial lytic enzyme) and exhibited
sustained release of the drug and inhibited E. coli growth for up to 3
days in vitro (Fig. 8Cii). The nanospheres were also loaded with lyso-
zyme, an antimicrobial enzyme, and showed a signiﬁcantly higher an-
timicrobial activity compared with free lysozyme, which was not able
to achieve the minimum inhibitory concentration of 700 μg/mL even at
very high concentrations of 2mg/mL (Fig. 8Ciii) [195]. To study the
antibacterial eﬃcacy ex vivo, a rat small intestine infection model was
used. The rough silica spheres exhibited more than two orders of
magnitude lower E. coli count compared to phosphate buﬀer solution
and free lysozyme administration, and 30 times lower count compared
to smooth hollow silica spheres loaded with lysozyme (Fig. 8Ciii) [195].
Bioadhesives have been also used for drug delivery through the
incorporation of drug-loaded microspheres. Sensoy et al. created
bioadhesive sulfacetamide sodium (SA) microspheres for eﬀective de-
livery of ocular keratitis by increasing the bioavailability of the drugs
on the ocular surface [197]. Spray drying was used to fabricate mi-
crospheres using diﬀerent ratios of a combination of polymers with
mucoadhesive properties, such as polycarbophil, hydroxypropylmethyl
cellulose, and pectin, and drugs. The most suitable polymer-to-drug
ratio for ocular applications was of 2:1. This polymer-drug ratio (sus-
pended in light mineral oil) was used in vivo to treat bacterial keratitis
on New Zealand male rabbit eyes infected by S. aureus or Pseudomonas
aeruginosa. In both infection models, a signiﬁcant decrease in bacteria
count was observed in eyes treated with SA-microspheres versus those
treated with free SA, illustrating the eﬀectiveness of SA-loaded
A
i
B C
i
ii
iiiiii
ii
i
ii
iii
Fig. 8. Examples of bioadhesives used for drug delivery. (A) A bioadhesive to lower the IOP. (i) TEM images of the brimonidine-loaded chitosan (CS) and alginate
(ALG) NPs, (ii) Release proﬁle of brimonidine from the NPs eye drops, gel and in situ, (iii) IOP eﬀect of the formulation. Adapted from Ibrahim et al. [193] with
permission from ARVO, copyright 2015; (B) (i) Schematic of the NP-gel system, consisting of ciproﬂoxacin-loaded NPs in a 3D adhesive hydrogel, (ii) Release proﬁle
of ciproﬂoxacin in vitro, (iii) Eﬀect of the adhesive on E. coli bacterial ﬁlm in vivo. Adapted from Zhang et al. [194] with permission from American Chemical Society,
copyright 2016; (C) (i) Schematic of the hollow nanocarriers loaded with lysozyme, with rough surface to enhance adhesion to bacteria, (ii) Release proﬁle of
lysozyme in vitro for smooth silica hollow spheres (S-SHSs), rough mesoporous silica hollow spheres (R-MSHSs), and rough mesoporous silica hollow spheres with
blocked shell (R-MSHSs-B) (iii) Antibacterial eﬃcacy of the adhesive in vitro toward E. coli. Adapted from Song et al. [195] with permission from American Chemical
Society, copyright 2016.
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microspheres in the treatment of ocular keratitis [197].
A bioadhesive ophthalmic drug insert (BODI) was developed by
Baeyens et al. [198]. The placement of this soluble insert in the lower
cul-de-sac of the eye allows for prolonged release of gentamicin, which
addressed the inconvenience associated with several daily applications
of eye drops over a prolonged period of time that is normally required
to treat ocular diseases. The clinical eﬃcacy of BODI was compared
with that of the classical eye drop treatment Tiacil on dogs. BODI was
shown to be as eﬀective as Tiacil in treating the symptoms of the ex-
ternal ophthalmic diseases, conjunctivitis and keratoconjunctivitis
sicca, with the advantage of providing the treatment in a single appli-
cation [198].
By creating novel and eﬀective bioadhesives for drug-delivery, it is
possible to overcome some of the setbacks associated with conventional
ocular drug delivery systems such as solutions and suspensions. This
section discussed ocular bioadhesives that are capable to achieve their
desired physiological outcomes through their inherent properties or
through the integration of drugs in their formulations. The use of micro-
and nanoparticles in these formulations provides great ﬂexibility to the
design of drug-loaded ocular adhesives, by providing additional means
to control (ﬁne-tune) drug release and improve residence time, eﬃcacy,
or adhesive strength. In the years to come, adhesives used for appli-
cations other than ocular drug delivery, will be tailored towards ocular
applications through simple design modiﬁcations.
5. Bandage contact lenses and prefabricated patches
Over the last decade, the number of contact lens (CL) users has
tremendously increased, and currently over 70 million people world-
wide wear CLs [199]. Bandage CLs, speciﬁcally, have been used over
the last four decades in clinic after refractive surgery to aid patient
recovery. They provide a physical barrier that allows the tissue to heal,
and apply pressure to relieve pain [200]. Generally, the patient needs to
continuously use soft bandage CLs after ophthalmic surgery, in order to
sustain suﬃcient ocular surface hydration, protect the eye from ne-
crosis, and improve comfort after surgery [201]. Silicon hydrogels are
the most commonly used materials to fabricate CLs because of their
softness (Modulus: 0.5–1.4MPa), ﬂexibility, water content (24–47%),
transparency, and high gas permeability (oxygen permeability, DK: 60-
14) which are key characteristics for bandage CLs. Non-silicon CLs are
also used after surgery. However, their use for extended period leads to
tissue swelling due to their low gas permeability. Balaﬁlcon A (Pure
Vision, Bausch & Lomb), Lotraﬁlcon A (Night & Day, Ciba Vision), and
Lotraﬁlcon B (O2Optix, CIBA Vision) are silicone hydrogels approved by
the FDA for use as bandage CLs for extended period of time (6, 30, and
30 days after refractive surgery, respectively) [200,202,203].
CL technology has advanced at a rapid pace in various innovative
directions, including as drug delivery systems [204,205], delivery of
antimicrobial agent [206], biosensors [199,200], and electronic dis-
plays [199,207]. These technologies will certainly substantially beneﬁt
the ocular wound care arena in the short term. Several examples of new
technological functionalities incorporated into CLs are discussed in this
section (Fig. 9).
CLs have been widely studied as eﬀective drug delivery systems.
This is mainly due to limitations of traditional ophthalmic drug delivery
methods, (e.g. topical delivery using eye drops), such as: low eﬃciency
patient noncompliance, and poor ocular drug bioavailability (less than
5%) [208]. Several groups have attempted to develop CLs for drug
delivery applications using diﬀerent strategies such as drug soaking
[204,209,210], using vitamin E as a diﬀusion barrier [211–214], NP
laden CLs (Lipid-based and polymers) [215–219], molecular imprinting
[80,220–222], and layer-by-layer platforms [223,224]. For instance,
Carreira et al. developed a novel bandage CL made from PVA and
chitosan and incorporated with vancomycin using a “soak and release”
technique to prevent inﬂammation after corneal substitution [225].
The incorporation of NPs in formulations such as microemulsions,
liposomes, cyclodextrins and polymer-based NPs into the CL structure is
also a promising method for eﬃcient drug delivery into the eye. These
MP-formulations exhibit a high drug-loading capacity, thermodynamic
stability, and high versatility for loading both hydrophilic and hydro-
phobic drugs (Fig. 9A) [208]. Molecular imprinting is another tech-
nique used for the development a drug template on a ﬂexible network
of macromolecules (e.g. polymers) based on a lock and key concept.
According to this theory, only the enzymes/molecules (keys) with
particular active binding sites and unique geometrical structures are
suitable for a speciﬁc substrate (locks). Therefore, molecules with in-
correct shape or functionality cannot be recognized to by the substrate
[204]. This technique provides higher drug aﬃnity (generally through
hydrogen binding, ionic or hydrophobic interactions) and improves the
uptake and sustained release of the drug [204]. Based on these tech-
nique, one or more functional monomers is polymerized in the presence
of a drug template (Fig. 9B). The functional monomers need to possess
some characteristics such as chemical compatibility with the lens
composition and high aﬃnity for the drug template. Acrylic acid, me-
thacrylic acid, acrylamide, methyl methacrylate, hydroxyethyl metha-
crylate and N-vinylpyrrolidone are the most widely used functional
monomers for ophthalmic drug delivery in CLs [205].
Ocular diagnosis and biosensing are another promising applications
of CLs. For instance, Yao et al. designed a CL with an integrated am-
perometric sensor in order to monitor and analyze the glucose com-
position of tears of diabetic patients (Fig. 9Ci-ii) [226]. The engineered
biosensor showed a minimum detection capability of less than 0.01mM
glucose, a high linearity in the normal range of tear glucose con-
centration (0.1–0.6 mM), as well as high selectivity in the presence of
interfering agents (Fig. 9Ciii-iv) [226,229]. Chen et al. reported a
sensor to measure IOP intended to monitor glaucoma [230]. This sensor
was integrated to a silicon CL and responded to changes in the eye
curvature with high sensitivity (> 200 ppm/mmHg of IOP in ex vivo
porcine eyes) and linearity in real time. Recently, CLs have been in-
tegrated into sensors for diﬀerent molecules such as ions, proteins, urea,
pyruvate, dopamine, ascorbate and lactate [199]. This is likely due to
new technologies and developments in electronics, micro/nanofabri-
cation techniques, biomaterials and biosensors [199]. Future advances
along this line could enable the diagnosis and even treatment of dif-
ferent diseases such as Meibomian gland disease, AIDS, diabetes,
cancer, glaucoma, ocular chlamydia trachomatis and keratoconus
[199].
Advances in telecommunications are also impacting CL technology.
For instance, Lingley et al. reported a design of a CL that was able to
display a single pixel wirelessly [227]. They assembled a chip con-
taining an Indium gallium nitride/Gallium nitride (InGaN/GaN) LED
onto a polyethylene terephthalate (PET) sheet, emitting light when
voltage was applied (Fig. 9Di). The integration of an antenna, a wireless
power harvesting system, the LED, and the polymeric substrate resulted
in a CL capable of displaying a single pixel. The CL was operable and
controllable remotely on live rabbit eyes (Figure Dii). These technolo-
gical advances aim to develop a new generation of wearable CLs able to
display multipixel images and interactive information.
In addition to bandage CLs, prefabricated patches have been ex-
tensively used for ocular tissue regeneration. A group of these pre-
fabricated patches are inspired by the gecko's foot-hair as a successful
strategy to enhance the adhesion of the patch to both wet and dry
surfaces [231]. Using this technique, Rizwan et al. engineered a nano-
patterned and bioactive patch that was used as an implantable cell-
carrier construct for corneal repair [228] (Fig. 9Ei). The engineered
patch exhibited high adhesion strength and cell/patch interaction. In
addition, it induced corneal defect regeneration, suggesting its potential
as a micro/nanoengineered patch for corneal endothelial dysfunction
repair (Fig. 9Eii-iii) [228]. Vitrigel membranes are another group of
prefabricated patches (described in section 3.1.3) [163,232]. Chae et al.
developed a collagen vitrigel membrane that could help reconstruction
of the corneal epithelial layer and prevent epithelial hypertrophy,
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minimizing complications such as immune rejection or delay in epi-
thelialization [163]. Due to the high transparency, low thickness, and
high biocompatibility of the prefabricated membranes, they are pro-
mising biomaterials for corneal grafting as well as good alternative for
corneal regeneration [163].
In the years to come, many more applications are expected to ex-
pand the physicians’ resources to attend to patient needs after ocular
surgery or injury. For example, the use of smart CLs could be extended
to monitor the evolution of the ocular healing process, and to deliver,
on-demand, the proper sequence of chemical and physical cues to favor
tissue repair.
6. Decellularized corneas
Despite the numerous advances in biomaterials science discussed
above, biomaterial-based engineered corneas often do not faithfully
replicate the microenvironment and microarchitecture of the cornea.
Consequently, many eﬀorts to repair corneal blindness have remained
focused on corneal transplantation. Traditionally, corneal transplanta-
tions have relied on allogeneic donors. However, alternative ap-
proaches have been investigated as there is an insurmountable donor
shortage. The transplantation of porcine corneas has particularly gained
attention due to their availability, low cost, and comparable refractive
and dimensional nature. However, porcine corneas are inherently
Fig. 9. Examples of CLs and prefabricated patches. (A) Schematic of the NP-laden CLs, using nanostructures such as liposomes, cyclodextrins and micelles. (B)
Schematic of the molecularly imprinted polymers used for highly selective drug delivery systems in CLs. (C) (i) Scheme and (ii) images of a CL with an integrated
amperometric sensor for glucose monitoring and analysis. (iii) Linear correlation of current versus glucose concentrations (0.01–0.07mM range) and, (iv) sensor
accuracy and repeatability in the presence of interfering agents. Adapted from Yao et al. [226] with permission from Elsevier, copyright 2011. (D) LED display in a
contact lens; (i) polyethylene terephthalate (PET) chip containing a LED with and without voltage application, (ii) contact lens device containing a LED, and anthena
and a power harvesting system to display a single pixel wirelessly and its successful operation on a live rabbit eye. Adapted from Lingley et al., 2011 [227] with
permission from IOP, copyright 2011. (E) (i) Representative images of nanopatterned adhesive and bioactive patch used for corneal tissue engineering applications.
(ii) An optical coherence tomography (OCT) image of implanted nanopatterned patch in rabbit eye at day 10 of the study. (iii) Slit lamp images of the regeneration
process of rabbit corneas at diﬀerent time points after implantation of nanopatterned patch. Adapted from Rizwan et al. [228] with permission from Elsevier,
copyright 2017.
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xenogeneic, and decellularization is required prior to medical use.
Numerous decellularization techniques including chemical, phy-
sical, and enzymatic approaches have been developed over the years.
Chemical approaches such as ionic detergents (e.g. sodium dodecyl
sulfate) have been used on full-thickness porcine corneas to solubilize
cellular membranes and remove α-Gal in, while leaving the cornea's
architecture and structural protein such as collagens, laminins, and ﬁ-
bronectins largely intact [233]. Although anionic detergents such as
Triton X-100 and zwitterionic detergents such as CHAPS have the
capability to dissolve cell membranes while keeping the integrity of the
extracellular matrix, they are reported to be less eﬀective for corneal
decellularization than ionic detergents (which tend to denaturate pro-
teins). Speciﬁcally, current protocols leave a signiﬁcant fraction of cells
alive or leave numerous cell fragments behind, which can induce an
immune response [234]. Cell lysation using hypotonic or hypertonic
treatments has been proven to be eﬀective and maintain the cornea's
structure, and though nuclear fragments are left behind, this can be
remedied by the inclusion of nucleases [235].
Other chemical approaches include exposing corneas to chelating
agents (e.g. ethylenediaminetetraacetic acid), alcohols (e.g. ethanol),
bases (e.g. ammonium hydroxide), or acids (e.g. peracetic acid). Many
studies have also explored combinations of decellularization techni-
ques, in particular, chelating agents are often combined with enzymes,
and detergents are often combined with physical methods (e.g. ultra-
high hydrostatic pressures). Physical decellularization of corneal tissues
can be based on snap freezing and/or lyophilizing or applying hydro-
static pressure, both of which disrupt the cell membrane [236–238].
These techniques can induce swelling due to changes in the cornea's
architecture (e.g. increasing its porosity), and loss of structural protein
such as glycosaminoglycans [239]. Enzymatic decellularization can be
achieved using dispases, serine proteases, nucleases, and phospholi-
pases. Interestingly, human serum is known to contain numerous en-
zymes including nucleases, and has been shown to eﬀectively decel-
lularize corneas [240]. In addition to the mentioned techniques,
corneas can be gamma-irradiated to extend their shelf-life and reduce
the risk of disease transmission [241].
Despite the claimed eﬃciencies of the decellularization protocols,
the prevention of swelling, maintenance of architecture, preservation of
transparency, and prevention of the loss of matrix proteins have re-
mained common challenges. Biomaterials have been used to mitigate
these drawbacks. For example, the polysaccharide dextran has been
used to prevent corneal swelling and changes in the cornea's ultra-
structure [242]. In addition, decellularized tissue scaﬀolds have been
combined with HA to replace the lost structural proteins and to more
eﬀectively retain growth factors of choice [243,244]. Although several
studies have demonstrated that this approach holds great promise for
treatments based on decellularized skin, eﬀorts to determine the clin-
ical potential of combinations of decellularized corneas and biomater-
ials have lagged behind. In addition, combining corneas with adhesive
hydrogels could potentially increase successful grafting, drive suture-
less applications, and steer encapsulated donor cells or recruited host
cells.
7. Conclusion and outlook
The structural uniqueness of the human eye which enables vision is
the driving force that pushes the scientiﬁc community to seek novel
solutions that replace conventional surgical approaches to managing
serious ocular injury and disease. Numerous eﬀorts have been devoted
to prepar synthetic-based and naturally derived adhesives (e.g. cya-
noacrylates, PEG based adhesives, protein- and polysaccharide-based
adhesives), which address some of the risks and shortcomings asso-
ciated with the application of sutures (Table 1). Owing to their distinct
properties, each of these adhesives shows promise for use in diﬀerent
clinical settings, where retention, adhesiveness, or mechanical supports
are required. As a result, the state-of-the-art in ocular wound care has
evolved considerably through the years from conventional suturing to
the use of rationally designed biomaterials. Cyanoacrylates, often used
as oﬀ-label adhesives for ocular wound closure, will be substantially
improved or replaced for other ‘eye-friendly’ options such as new nat-
ural or synthetic polymeric materials.
In the near future, a new generation of ocular adhesives with tun-
able properties that not only fulﬁll the required design criteria, but also
actively favor tissue repair will reach the marketplace. We can also
envisionthe development of ocular scaﬀolds holding stem cells that can
undergo diﬀerentiation and proliferation, or smart CLs that will
monitor and speed up the wound healing process through on-line sen-
sing and on-demand drug delivery. These and other examples of the
integration of biomaterial engineering, electronics, micro- and nano-
technologies are expected to improve the healing process and will
embody a new stage in ocular medicine with improved patient out-
come.
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